32 results Forewarned is forearmed: RPM still top of mind The clock is ticking for companies to set the record straight on resale price maintenance (RPM). Retailers must be able to determine their own retail prices without any direct or indirect meddling by suppliers. Dawn raid drama: bycatch and data rooms Beware of the fine line in antitrust investigations between illegal fishing expeditions and accidental discoveries pointing at a separate antitrust infringement. If at first you don’t succeed ... Court unblocks two blocked healthcare mergers The ACM needs to ‘try, try again’ when assessing healthcare mergers. The Rotterdam District Court overturned two of the ACM’s healthcare merger prohibitions within less than two months. Euronext/Stibbe ECM Seminar on Prospectus Disclosure and ESG On Tuesday 12 September 2023, from 15:30 to 17:30, we will organise a seminar on Prospectus Disclosure and ESG at our Amsterdam office, together with Euronext Amsterdam. The latest Legal Updates straight to your mailbox We publish high-quality legal knowledge and insights on our website on a daily basis. If you would like to be promptly informed about the latest developments within your areas of interest, we invite you to sign up for our Legal Updates. Competition law in 2024: putting theory into practice 2023 marked the near finale of the European Commission’s overhaul of its competition policy, leaving only a few loose ends to tie up in 2024/2025. It is now time to watch theory be put into practice by the competition authorities and at the courts. 2022: the big reveal of 2021’s competition law promises 2021 was riddled with sneak previews of a “review of competition policy tools with unprecedented scope and ambition”. Court rules ACM can use accidental evidence found in dawn raids While skimming through employees’ chat conversations and e-mails, it is not uncommon for competition authorities to stumble across other potential antitrust violations, separate from the initial scope of the search. ACM issues first excessive pricing fine in pharma On 1 July 2021, the Dutch Authority for Consumers and Markets (ACM) imposed a fine of EUR 19.5 million on drug manufacturer Leadiant for excessive pricing of their orphan drug CDCA-Leadiant. Qualcomm falls prey to EU court’s predatory pricing ruling The EU General Court confirms that Qualcomm’s below-cost pricing strategy designed to eliminate competition was predatory. This judgment, the first of its kind in over a decade, provides useful guidance on predatory pricing practices. Stibbe Capital Markets Seminar On Thursday 20 June 2024, Stibbe will host its annual Capital Markets Seminar. This year, the seminar will discuss “The case for Amsterdam listings – now and in the future”. Belgian watchdog tackles bid rigging In recent cases in the fire protection and private security sectors, the Belgian Competition Authority has made the prosecution of bid-rigging one of its top priorities, imposing hefty fines on infringers for their participation in cartel schemes. ACM rolls the dice on roll-up strategies For the first time, the Dutch Authority for Consumers and Markets conducted a merger review involving a ‘roll-up strategy’. The outcome of another roll-up strategy merger assessment is pending. Sharing is caring? Commission can take over NCA probe The EU case cooperation mechanism does not create any rights for companies to have their case dealt with by a particular competition authority. Companies should therefore factor the dynamics of this cooperation mechanism into their defence strategies. Corona-special Sinds de uitbraak van het coronavirus als veroorzaker van de ziekte COVID-19 lijkt alles anders. Tijdens zijn persconferentie op 31 maart jongstleden verwoordde minister-president Rutte dat door de huidige crisis, als gevolg van de uitbraak van het corona Key considerations for management and owners of Dutch privately held companies in distress due to COVID-19 The COVID-19 pandemic has a significant and immediate adverse effect on many companies in different industries. Many PE portfolio companies are particularly vulnerable given the typical high leverage finance structure and inherent need to maintain cash fl Tapping the Equity Capital Markets in Times of Economic Uncertainty This short note discusses a few thoughts for Dutch issuers that are considering a capital raise in order to strengthen their balance sheet, with or without the need to publish a prospectus. Although the markets for equity issuances are currently by and la Dividend in coronatijd? De invloed van de coronacrisis op het al dan niet doen van een uitkering aan aandeelhouders is groot. Veel bestuurders zullen de dividendvoorstellen die in aanloop naar de jaarlijkse algemene vergadering of de jaarlijkse besluitvorming in het kader van he Pagination Current page 1 Page 2 Next page
Forewarned is forearmed: RPM still top of mind The clock is ticking for companies to set the record straight on resale price maintenance (RPM). Retailers must be able to determine their own retail prices without any direct or indirect meddling by suppliers.
Dawn raid drama: bycatch and data rooms Beware of the fine line in antitrust investigations between illegal fishing expeditions and accidental discoveries pointing at a separate antitrust infringement.
If at first you don’t succeed ... Court unblocks two blocked healthcare mergers The ACM needs to ‘try, try again’ when assessing healthcare mergers. The Rotterdam District Court overturned two of the ACM’s healthcare merger prohibitions within less than two months.
Euronext/Stibbe ECM Seminar on Prospectus Disclosure and ESG On Tuesday 12 September 2023, from 15:30 to 17:30, we will organise a seminar on Prospectus Disclosure and ESG at our Amsterdam office, together with Euronext Amsterdam.
The latest Legal Updates straight to your mailbox We publish high-quality legal knowledge and insights on our website on a daily basis. If you would like to be promptly informed about the latest developments within your areas of interest, we invite you to sign up for our Legal Updates.
Competition law in 2024: putting theory into practice 2023 marked the near finale of the European Commission’s overhaul of its competition policy, leaving only a few loose ends to tie up in 2024/2025. It is now time to watch theory be put into practice by the competition authorities and at the courts.
2022: the big reveal of 2021’s competition law promises 2021 was riddled with sneak previews of a “review of competition policy tools with unprecedented scope and ambition”.
Court rules ACM can use accidental evidence found in dawn raids While skimming through employees’ chat conversations and e-mails, it is not uncommon for competition authorities to stumble across other potential antitrust violations, separate from the initial scope of the search.
ACM issues first excessive pricing fine in pharma On 1 July 2021, the Dutch Authority for Consumers and Markets (ACM) imposed a fine of EUR 19.5 million on drug manufacturer Leadiant for excessive pricing of their orphan drug CDCA-Leadiant.
Qualcomm falls prey to EU court’s predatory pricing ruling The EU General Court confirms that Qualcomm’s below-cost pricing strategy designed to eliminate competition was predatory. This judgment, the first of its kind in over a decade, provides useful guidance on predatory pricing practices.
Stibbe Capital Markets Seminar On Thursday 20 June 2024, Stibbe will host its annual Capital Markets Seminar. This year, the seminar will discuss “The case for Amsterdam listings – now and in the future”.
Belgian watchdog tackles bid rigging In recent cases in the fire protection and private security sectors, the Belgian Competition Authority has made the prosecution of bid-rigging one of its top priorities, imposing hefty fines on infringers for their participation in cartel schemes.
ACM rolls the dice on roll-up strategies For the first time, the Dutch Authority for Consumers and Markets conducted a merger review involving a ‘roll-up strategy’. The outcome of another roll-up strategy merger assessment is pending.
Sharing is caring? Commission can take over NCA probe The EU case cooperation mechanism does not create any rights for companies to have their case dealt with by a particular competition authority. Companies should therefore factor the dynamics of this cooperation mechanism into their defence strategies.
Corona-special Sinds de uitbraak van het coronavirus als veroorzaker van de ziekte COVID-19 lijkt alles anders. Tijdens zijn persconferentie op 31 maart jongstleden verwoordde minister-president Rutte dat door de huidige crisis, als gevolg van de uitbraak van het corona
Key considerations for management and owners of Dutch privately held companies in distress due to COVID-19 The COVID-19 pandemic has a significant and immediate adverse effect on many companies in different industries. Many PE portfolio companies are particularly vulnerable given the typical high leverage finance structure and inherent need to maintain cash fl
Tapping the Equity Capital Markets in Times of Economic Uncertainty This short note discusses a few thoughts for Dutch issuers that are considering a capital raise in order to strengthen their balance sheet, with or without the need to publish a prospectus. Although the markets for equity issuances are currently by and la
Dividend in coronatijd? De invloed van de coronacrisis op het al dan niet doen van een uitkering aan aandeelhouders is groot. Veel bestuurders zullen de dividendvoorstellen die in aanloop naar de jaarlijkse algemene vergadering of de jaarlijkse besluitvorming in het kader van he